Publication date: 31/08/2017
Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that it will report its half-year 2017 results and outlook for the remainder of the year on 7 September 2017 at 07:00h CEST.
The Biocartis management team will host a conference call with live webcast presentation on the day of the results announcement, 7 September 2017, at 14:00h CEST / 13:00h BST (UK) / 08:00h EDT (US). The live webcast can be accessed here. If you would like to participate in the questions and answers session, please dial in 5-10 minutes prior to the start time using the numbers below and confirmation code 4254599.
Participants, New York, US: +1 212 444 0896
Participants, London, UK: +44 (0)20 3427 1902
Participants, Paris, France: +33 (0)1 76 77 22 24
Participants, Amsterdam, Netherlands: +31 (0)20 716 8256
Participants, Brussels, Belgium: +32 (0)2 404 0662
The conference call and webcast will be conducted in English. A replay of the webcast will be available on the Biocartis investors website shortly after.
Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla(TM) platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis launched the Idylla(TM) platform in September 2014. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest growing and largest segments of the MDx market worldwide. Today, Biocartis offers ten oncology tests and two infectious disease tests in Europe. More information: www.biocartis.com. Press Photo Library available here. Follow us on Twitter: @Biocartis_.